Folic acid supplementation in early second trimester and the risk of preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 1, 2008, Pages 45.e1-45.e7

  Wen, Shi Wu ^a,b   Chen, Xi Kuan ^a,b   Rodger, Marc ^b,c   Rennicks White, Ruth ^a,b   Yang, Qiuying ^a,b   Smith, Graeme N ^d   Sigal, Ronald J ^b,c,e   Perkins, Sherry L ^c   Walker, Mark C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d KINGSTON GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

5, 10 methylenetetrahydrofolate reductase; folic acid; homocysteine; preeclampsia; supplementation

Indexed keywords

FOLIC ACID;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; MEDICAL RECORD; NUTRITIONAL SUPPORT; PREECLAMPSIA; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; VALIDATION STUDY; VITAMIN SUPPLEMENTATION;

EID: 37349000559     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.06.067     Document Type: Article

References (25)

1. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77 (2002) 67-75
2. Wilson B.J., Watson M.S., Prescott G.J., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 326 (2003) 845
3. Barker D.J.P. Fetal programming and public health. In: O'Brien P.M.S., Wheeler T., and Barker D.J.P. (Eds). Fetal programming: influences on development and disease in later life (1999), RCOG Press, London 3-11
4. Roberts J.M., and Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol 24 (2004) 557-564
5. Bodnar L.M., Tang G., Ness R.B., Harger G., and Roberts J.M. Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 164 (2006) 470-477
6. Ashworth J.R., Warren A.Y., Johnson I.R., and Baker P.N. Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynecol 105 (1998) 459-461
7. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 277 (1997) 1775-1781
8. Ray J.G., and Laskin C.A. Folic acid and homocysteine metabolic defects and the risk of placenta abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 20 (1999) 519-529
9. Roberts J.M., Taylor R.M., and Goldfein A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 4 (1991) 700-708
10. Olthof M.R., Bots M.L., Katan M.B., and Verhoef P. Effect of folic acid and betaine supplementation on flow-mediated dilation: a randomized, controlled study in healthy volunteers. PLoS Clin Trials 1 (2006) e10
11. Donnelly J.G., and Rock G.A. Genetic determinants of heritable venous thrombosis: genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations. Clin Biochem 32 (1999) 223-228
12. Health Canada. Canadian Perinatal Health Report 2003 (2003), Ministry of Public Works and Government Services Canada, Ottawa, Canada
13. Conde-Agudelo A., Belizan J.M., and Lammers C. Maternal-perinatal morbidity and mortality associated with adolescent pregnancy in Latin America: cross-section study. Am J Obstet Gynecol 192 (2005) 342-349
14. Powers R.W., Dunbar M.S., Gallaher M.J., and Roberts J.M. The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy. Obstet Gynecol 101 (2003) 762-766
15. Anothiades C., Shirodaria C., Warrick N., Cai S., de Bono J., and Lee J. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114 (2006) 1193-1201
16. Rimm E.B., Willett W.C., Hu F.B., et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279 (1998) 359-364
17. Title L.M., Ur E., Giddens K., McQueen M.J., and Nassar B.A. Folic acid improves endothelial dysfunction in type 2 diabetes-an effect independent of homocysteine-lowering. Vasc Med 11 (2006) 101-109
18. Walker M.C., Smith G.N., Perkins S.L., Keely E.J., and Garner P.R. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 180 (1999) 660-664
19. Hogg B.B., Tamura T., Johnston K.E., Dubard M.B., and Goldenberg R.L. Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol 83 (2000) 805-809
20. Powers R.W., Evans R.W., Majors A.K., et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 179 (1998) 1605-1611
21. Hietala R., Turpeinen U., and Laatikainen T. Serum homocysteine at 16 weeks and subsequent preeclampsia. Obstet Gynecol 97 (2001) 527-529
22. Zuckerman B., Frank D.A., Hingson R., et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320 (1989) 762-768
23. Poston L., Briley A.L., Seed P.T., Kelly F.J., and Shennan A.H. Vitamins in pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomized placebo-controlled trial. Lancet 367 (2006) 1145-1154
24. Rumbold A.R., Crowther C.A., Haslam R.R., Dekker G.A., and Robinson J.S. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 354 (2006) 1796-1806
25. Ray J.G., and Mamdani M.M. Association between folic acid food fortification and hypertension or preeclampsia in pregnancy. Arch Intern Med 162 (2002) 1776-1777